Advertisement

Pathology & Oncology Research

, Volume 25, Issue 2, pp 487–492 | Cite as

Antithymocyte Globuline Therapy and Bradycardia in Children

  • Krisztián KállayEmail author
  • Dávid Zakariás
  • Katalin Csordás
  • Gábor Benyó
  • Csaba Kassa
  • János Sinkó
  • Anita Stréhn
  • Orsolya Horváth
  • Barna Vásárhelyi
  • Gergely Kriván
Original Article
  • 62 Downloads

Abstract

In antithymocyte globulin (ATG) treated patients occasionally bradycardia has been noticed. Therefore, we retrospectively analyzed the occurrence of bradycardia in ATG-treated children. Using medical records between 2007 and 2012 we identified children undergoing a combined therapy with ATG and glucocorticoids (ATG group, n = 22). The incidence of bradycardia was compared to that registered in children treated with glucocorticoids alone (glucocorticoid alone group, n = 21). Heart rates (HR) were registered before and on days 0–3, 4–7 and 8–14 after the ATG or steroid administration. The rate of bradycardic episodes was higher during ATG therapy than in the steroid alone group, while severe bradycardia occurred only in the ATG group (97 versus 32, p = 0.0037, and 13 versus 0, p = 0.0029, respectively). There was an interaction between the time and treatment group on HR (p = 0.046). Heart rates in ATG and steroid alone groups differed significantly on day 0–3 and day 4–7 (p = 0.046, p = 0.006, respectively). Within the ATG group HR was lower on days 4–7 compared to the days before and the days 8–14 values (p < 0.001, 95%CI: 0.020–0.074). These findings indicate that transient asymptomatic bradycardia is probably more common with ATG therapy than previously reported. HR should be closely monitored during and after ATG therapy.

Keywords

Antithymocyte globulin ATG Bradycardia Children 

Notes

Author Contributions

All authors have contributed substantially in the conception and design of the study. They all participated actively in the writing and approving of the manuscript.

Compliance with Ethical Standards

Conflict of Interest

The authors report no conflict of interest.

Ethical Approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For this type of study formal consent is not required.

References

  1. 1.
    George B, Mathews V, Viswabandya A, Lakshmi KM, Srivastava A, Chandy M (2010) Allogeneic hematopoietic stem cell transplantation is superior to immunosuppressive therapy in Indian children with aplastic anemia--a single-center analysis of 100 patients. Pediatr Hematol Oncol 27(2):122–131CrossRefGoogle Scholar
  2. 2.
    Karapinar DY, Karadaş N, Ay Y, Akin M, Balkan C, Aydinok Y, Kavakli K (2014) Rabbit antithymocyte globulin treatment in childhood acquired severe aplastic anemia. Pediatr Hematol Oncol 31(1):20–28CrossRefGoogle Scholar
  3. 3.
    Jiang S, Wang Y, Shi W, Shao Y, Qiao X, Lin J, Kuang H, Xie X (2009) The benefit of ATG in immunosuppressive therapy of children with moderate aplastic anemia. Pediatr Hematol Oncol 26(5):313–320CrossRefGoogle Scholar
  4. 4.
    Deyell RJ, Shereck EB, Milner RA, Schultz KR (2011) Immunosuppressive therapy without hematopoietic growth factor exposure in pediatric acquired aplastic anemia. Pediatr Hematol Oncol 28(6):469–478CrossRefGoogle Scholar
  5. 5.
    Scheinberg P, Townsley D, Dumitriu B, Scheinberg P, Weinstein B, Rios O, Wu CO, Young NS (2014) Horse antithymocyte globulin as salvage therapy after rabbit antithymocyte globulin for severe aplastic anemia. Am J Hematol 89(5):467–469CrossRefGoogle Scholar
  6. 6.
    Scheinberg P, Nunez O, Weinstein B, Scheinberg P, Biancotto A (2011) Wu CO, et al. horse versus rabbit antithymocyte globulin in acquired aplastic anemia. N Engl J Med 365(5):430–438CrossRefGoogle Scholar
  7. 7.
    Godown J, Deal AM, Riley K, Bailliard F, Blatt J (2011) Worsening bradycardia following antithymocyte globulin treatment of severe aplastic anemia. J Pediatr Pharmacol Ther 16(3):218–221Google Scholar
  8. 8.
    Tvede N, Nielsen LP, Andersen V (1986) Bradycardia after high-dose intravenous methylprednisolone therapy. Scand J Rheumatol 15(3):302–304CrossRefGoogle Scholar
  9. 9.
    Taylor MR, Gaco D (2013) Symptomatic sinus bradycardia after a treatment course of high-dose oral prednisone. The Journal of Emergency Medicine 45(3):e55–e58CrossRefGoogle Scholar
  10. 10.
    Al Shibli A, Al Attrach I, Hamdan MA (2012) Bradycardia following oral corticosteroid use: case report and literature review. Arab Journal of Nephrology and Transplantation 5(1):47–49Google Scholar
  11. 11.
    Akikusa JD, Feldman BM, Gross GJ, Silverman ED, Schneider R (2007) Sinus bradycardia after intravenous pulse methylprednisolone. Pediatrics 119(3):e778–e782CrossRefGoogle Scholar
  12. 12.
    Michaelson ME (1972) MA;. Congenital complete heart block: an international study of the natural history. In: Clinics C (ed) Brest AE, MA. FA Davis, Philadelphia, p 85Google Scholar
  13. 13.
    Kugler J (1990) Sinus node dysfunction. In: Gilette PG, Jr AG (eds) Pediatric arrhythmias: electrophysiology and pacing. WB Saunders, Philadelphia, p 250Google Scholar
  14. 14.
    Fox R, Lumb MR, Hawkins DF (1990) Persistent fetal sinus bradycardia associated with maternal anti-Ro antibodies. Case report. Br J Obstet Gynaecol 97(12):1151–1153CrossRefGoogle Scholar
  15. 15.
    Brucato A, Cimaz R, Catelli L, Meroni P (2000) Anti-Ro-associated sinus bradycardia in newborns. Circulation 102(11):E88–E89CrossRefGoogle Scholar
  16. 16.
    Sacks JH, Samai C, Gomez K, Kanaan U (2013) Maternal antibody-associated fetal second-degree heart block and atrial flutter: case report and review. Pediatr Cardiol 34(8):2040–2043CrossRefGoogle Scholar
  17. 17.
    Rosenthal E (1998) New insights into the pathogenesis of anti-Ro antibody associated congenital complete heart block. Lupus 7(3):135–136CrossRefGoogle Scholar
  18. 18.
    Rein AJ, Mevorach D, Perles Z, Gavri S, Nadjari M, Nir A et al (2009) Early diagnosis and treatment of atrioventricular block in the fetus exposed to maternal anti-SSA/Ro-SSB/la antibodies: a prospective, observational, fetal kinetocardiogram-based study. Circulation 119(14):1867–1872CrossRefGoogle Scholar
  19. 19.
    Kelly EN, Sananes R, Chiu-Man C, Silverman ED, Jaeggi E (2014) Prenatal anti-Ro antibody exposure, congenital complete atrioventricular heart block, and high-dose steroid therapy: impact on neurocognitive outcome in school-age children. Arthritis Rheum 66(8):2290–2296CrossRefGoogle Scholar
  20. 20.
    Iida M, Inamura N, Takeuchi M (2006) Newborn infant with maternal anti-SSA antibody-induced complete heart block accompanying cardiomyopathy. Circulation Journal : Official Journal of the Japanese Circulation Society 70(1):147–149CrossRefGoogle Scholar
  21. 21.
    Costedoat-Chalumeau N, Georgin-Lavialle S, Amoura Z, Piette JC (2005) Anti-SSA/Ro and anti-SSB/la antibody-mediated congenital heart block. Lupus 14(9):660–664CrossRefGoogle Scholar
  22. 22.
    Costedoat-Chalumeau N, Amoura Z, Villain E, Cohen L, Piette JC (2005) Anti-SSA/Ro antibodies and the heart: more than complete congenital heart block? A review of electrocardiographic and myocardial abnormalities and of treatment options. Arthritis Research & Therapy 7(2):69–73CrossRefGoogle Scholar
  23. 23.
    Mohacsi P, Martinelli M, Banz Y, Boesch C (2012) The clinical relevance of antibody-mediated rejection: a new era of heart transplantation. European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery 42(6):1047–1049CrossRefGoogle Scholar
  24. 24.
    Daly KP, Chandler SF, Almond CS, Singh TP, Mah H, Milford E, Matte GS, Bastardi HJ, Mayer JE, Fynn-Thompson F, Blume ED (2013) Antibody depletion for the treatment of crossmatch-positive pediatric heart transplant recipients. Pediatr Transplant 17(7):661–669Google Scholar
  25. 25.
    Chih S, Tinckam KJ, Ross HJA (2013) Survey of current practice for antibody-mediated rejection in heart transplantation. Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg 13(4):1069–1074CrossRefGoogle Scholar
  26. 26.
    van der Gugten A, Bierings M, Frenkel J (2008) Glucocorticoid-associated bradycardia. J Pediatr Hematol Oncol 30(2):172–175CrossRefGoogle Scholar

Copyright information

© Arányi Lajos Foundation 2018

Authors and Affiliations

  • Krisztián Kállay
    • 1
    Email author
  • Dávid Zakariás
    • 1
  • Katalin Csordás
    • 1
  • Gábor Benyó
    • 1
  • Csaba Kassa
    • 1
  • János Sinkó
    • 1
  • Anita Stréhn
    • 1
  • Orsolya Horváth
    • 1
  • Barna Vásárhelyi
    • 2
  • Gergely Kriván
    • 1
  1. 1.Pediatric Hematology and Stem Cell Transplantation UnitUnited St. István and St. László HospitalBudapestHungary
  2. 2.Department of Laboratory MedicineSemmelweis UniversityBudapestHungary

Personalised recommendations